Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

Pages: 52 Published: November 30, 2018 Report Code: GDHC062SP

Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Scope

The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)

Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix

Forecasts are presented in pipeline forecast figures & detailed tables

‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided

Key Highlights

Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain

Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)

Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time

Reasons to Buy

Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher

Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market

Reviews ongoing lifecycle management strategies for existing players in the market

A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts

Key Players

Afimmune
Akarna Therapeutics
Akero Therapeutics
Albireo
Allergan
Allergan (acquired from
Ardelyx
Arisaph
AstraZeneca
BHV Pharma Inc
Bird Rock Bio/Janssen
BMS
Boehringer Ingelheim
Can-Fite BioPharma
Celgene
Cempra
Cerenis Therapeutics
ChemomAb
Cirius Therapeutics
CohBar
ConSynance Therapeutics
CymaBay Therapeutics
DeuteRx
Dr. Falk Pharma GmbH
DURECT Corporation
Eli Lilly
Enanta
Galectin Therapeutics
Galmed
Gemcabene
Genfit
Gilead
GRI Bio
HighTide Biopharma
Immune Pharmaceuticals Inc.
Immuron
Intercept
INVENT Pharmaceuticals
Inventiva
Ionis Pharma-ceuticals
Janssen
Madrigal
MediciNova
Metacrine
Mitsubishi Tanabe
Naia
NGM Biopharmaceuticals
Nitto Denko
NorthSea Therapeutics
Novartis
Novo Nordisk
NuSirt BioPharma
Oramed
Pfizer
Poxel
Sanofi
Second Genome
Shire
Sinew Pharma
Sucampo Pharmaceuticals
Synairgen
Taiwan Pharmaceuticals
Teva
Tiziana Life Sciences
Valbiotis
Viking Therapeutics
Virobay
Zafgen
Zydus Discovery

Table of Contents

• Introduction to Sociable Pharma’s ‘Competitor Landscape’

• Executive Summary (Go to Section)

– Key Events & Landscape Updates

• Landscape Updates (Go to Section)

– Order of Entry

– Key Competitor Market Entry Strategies

– Lifecycle Development

– Key Competitor ‘Direction of Travel’

• Pipeline Landscape (Go to Section)

– Pipeline Summary

• Appendix (Go to Section)

– Early Stage Pipeline ‘Watch List’

– Assumptions, Glossary & Abbreviations, and Notes

– Contact Details

$6,400

Can be used by individual purchaser only

$19,200

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.